Pfizer Overseas Pharmaceuticals v Eli Lilly and Company

Link copied
Case Copied 76 min read

FEDERAL COURT OF AUSTRALIA

Pfizer Overseas Pharmaceuticals v Eli Lilly and Company
[2005] FCAFC 224

PATENTS – validity – construction –  lack of inventive step – novelty – fair basis – sufficiency of description of invention – disclosure of best method of invention – date of assessment – false suggestion – patent for treatment of erectile dysfunction – common general knowledge at priority date – relevant prior art – use of evidence of overseas witnesses

Patents Act 1990 (Cth) s 18(1), s 40, s 7, s 138

Eli Lilly and Company v Pfizer Overseas Pharmaceuticals (2005) 218 ALR 408 cited
Bristol-Myers Squibb Company v FH Faulding & Co Limited (2000) 97 FCR 524 applied
Canadian General Electric Co Limited v Fada Radio Limited [1930] AC 97 cited
Hill & Evans (1862) 4 De G F & J 288; 45 ER 1195 cited
Aktiebolaget Hassle v Alphapharm Pty Ltd (200r) 212 CLR 411 applied
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 212 ALR 1 applied
Martin v Scribal Pty Ltd (1954) 92 CLR 17 applied
Welch Perrin & Co Pty Ltd v Worrel (1961) 106 CLR 588 cited
Interlego AG v Toltoys Pty ltd (1972) 130 CLR 461 applied
Décor Corp Pty Ltd v Dart Industries Inc (1988) 13 IPR 385 cited
Nesbit Evans Group Australia Pty Ltd v Impro Ltd (1997) 39 IPR 56 cited
Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd (2001) 207 CLR 1 cited
Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 cited
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 122 ALR 417 cited
Olin Corporation v Super Cartridge Co Pty Ltd (1977) 180 CLR 236 cited
Société Des Usines Chimiques RhônePoulenc v Commissioner of Patents (1958) 81 ALR 79 cited
Rehm Pty Ltd v Websters Security Systems (International) Pty Ltd (1988) 81 ALR cited
Minnesota Mining and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253 cited
WR Grace v Asahi Kasei (1993) AIPC 90-974 cited
Firebelt Pty Ltd v Brambles Pty Ltd (2002) 188 ALR 280 cited
Tidy Tea Ltd v Unilever Australia Ltd (1995) 32 IPR 405 cited
Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 cited
Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157 followed
Meyers Taylor Pty Ltd v Viccar Industries Ltd (1977) 137 CLR 228 cited
Flour Oxidizing Co Ltd v Carr & Co Ltd (1908) 25 RPC 428 cited
General Tire & Rubber Co v Firestone Tyre and Rubber Co Ltd [1972] RCP 457 cited
Imperial Chemical Industries Pty Ltd v Commissioner of Patents (2004) 213 ALR 399 cited
AMP Inc v Utilux Pty Ltd (1971) 45 ALJR 123 cited
British Dynamite Co v Krebs [1879] 13 RPC 190 cited
Esber v The Commonwealth (1992) 174 CLR 430 cited
Frederikshavn Vaerft A/S v Stena Rederi Aktiebolag (2002) 124 FCR 243 cited
Rescare Limited v Anaesthetic Supplies Pty Ltd (1992) 111 ALR 205 discussed
C Van Der Lely NV v Ruston’s…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Overseas Pharmaceuticals v Eli Lilly and Company and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] FCAFC 224
Decision Date

CaseChat Overview and Summary

Pfizer Overseas Pharmaceuticals, the respondent, appealed against a decision of the Federal Court of Australia that found claim 10 of their patent for a pharmaceutical composition to be invalid. Eli Lilly and Company, the appellant, sought to invalidate the patent on various grounds including lack of inventive step, insufficiency, and failure to fairly base the claims on the specification. The case involved a detailed understanding of the physiological and biochemical processes of erectile function in the human penis and the potential therapeutic use of PDE VA inhibitors.

The primary legal issue before the court was whether claim 10 of Pfizer's patent was valid. The court had to determine if the patent specification sufficiently disclosed the invention, if the invention was obvious, and if claim 10 was fairly based on the specification. The court also had to consider whether the patent disclosed a false suggestion and if it complied with the best method requirement.

The court found that Pfizer had successfully demonstrated error in the primary judge's finding regarding the lack of inventive step. However, it upheld the primary judge's finding that claim 10 was not fairly based on the specification. The court concluded that claim 10 was invalid due to the lack of fair basis and dismissed the appeal. The court ruled that each party should bear its own costs of the appeal due to the distribution of success and failure.

The court's decision was that the appeal be dismissed and that the parties bear their own costs of the appeal. This outcome ensures that Pfizer's patent claim 10 remains invalid due to the lack of fair basis in the specification.

Orders

Orders of the court

1. The appeal be dismissed.

2. The parties bear their own costs of the appeal.

Background

Background to the litigation

In the result claim 10 is invalid for want of fair basing. The appeal must therefore be dismissed. However as Lilly has failed on all the other points it has raised, the appropriate order is that each party bear its own costs of the appeal.Physiological and Bio-chemical Background In order to appreciate the issues on the appeal it is necessary to have a basic understanding of the physiological and biochemical processes at work in the erectile function of the human penis. Pfizer and Lilly prepared technical primers for the trial which, it was said, set out current knowledge. There was contention about whether some of the matters contained in the primers were known or formed part of general scientific knowledge as at June 1993 and May 1994. It was apparent, however, that the general descriptions of the processes at work in relation to erectile function as known at the time of the trial were not in dispute. The Court was also assisted by a PowerPoint presentation setting out essential elements of the relevant biochemical pathways. Two key diagrams from that presentation are set out at the end of these reasons so that the reader can better follow the discussion of the evidence and the submissions. The penis has three cylindrical masses of erectile tissue. They are enclosed in a fibrous membrane. The bulk of the penis comprises two erectile cylinders called the corpora cavernosa. They are paired and lie side by side. They are separated by an incomplete fibrous wall or septum. They communicate along three quarters of their length through small holes in the septum which allow them to operate as a single unit. A third cylinder called the corpus spongiosum surrounds and supports the urethra and sits in a groove created by the other two cylinders. It also keeps the urethra open during ejaculation. The three erectile cylinders comprise largely highly vascularised sinusoidal tissue. When the sinusoidal tissue fills with blood during sexual excitement the penis enlarges, becoming rigid and erect. Blood is supplied to the penis by arteries and exits the penis by veins. The process of erection or tumescence occurs when smooth muscle in the penis relaxes allowing the blood vessels to open up and blood to flow into the corpus cavernosum. Detumescence, which is the resting state, occurs when smooth muscle is contracted restricting blood flow to the penis and acting like a ligature. During tumescence the swelling of the corpus cavernosum reduces the ability of blood to drain from the penis so maintaining erection. The relaxation of smooth muscle is therefore critical to the erectile functioning of the penis. Smooth muscle is one of three basic types of muscle tissue found in vertebrates. The other two are skeletal muscle and cardiac muscle. Smooth muscle is found in many tissues and organs throughout the vascular system surrounding blood vessels. It is also found in the lungs, surrounding the airways such as bronchioles, in the gastrointestinal tract and in the uterus. It contracts or relaxes, without voluntary control, according to impulses from the autonomic nerve system. That is the part of the peripheral nervous system which is responsible, inter alia, for controlling the function of organs and other tissues within the body. The smooth muscle which surrounds the sinusoids and small arteries and in the corpora cavernosa is under the control of the autonomic nervous system.

Evidence

Evidence Before The Court

Turning to potential therapeutic use of PDE VA inhibitors, Murray observed that the only PDE VA inhibitor that had been clinically evaluated to the time of publication of his article was zaprinast. It had been used for adult asthmatics, to reduce bronchoconstriction induced by exercise but not that provoked by histamines. It had no effect on exercise induced asthma in children. He said (at 154): ‘However, when evaluating these results, it should be remembered that these were small clinical trials using a compound that may have actions other than PDE VA inhibition. Therefore, at present, PDE VA inhibitors must be considered to be compounds with potential rather than established clinical use.’He went on (at 154-155):‘Smooth muscle relaxation appears to be the most promising of the potential uses of PDE VA inhibitors, and possible therapeutic utilities could include vasodilation, bronchodilation, modulation of gastrointestinal motility and treatment of impotence. Although PDE VA inhibitors will relax most smooth muscle types in vitro, this does not necessarily mean that a nonselective action will be seen in vivo. Selective actions could be achieved by virtue of the fact that many of the effects of PDE VA inhibitors in a particular tissue are dependent on the level of guanylate cyclase activity. Thus, PDE VA inhibitors will have the greatest effect in cells and tissues that have a high guanylate cyclase activity, and there could be considerable value in a therapeutic agent that has little activity in its own right, but potentiates the effects of endogenous mediators.’In his final paragraph, Murray said: ‘In addition to smooth muscle relaxation, other therapeutic properties of PDE VA inhibitors could include analgesia and effects on platelet function. At present, the therapeutic potential of PDE VA inhibitors is largely based on the effects of one compound (ie, zaprinast), and a clearer picture will be obtained when other rationally designed PDE VA inhibitors become available.’The Evidence at Trial The reasons for judgment of the learned trial judge were succinct and it is necessary in considering them, on appeal, to have an appreciation of the range and content of the evidence that was placed before him. What follows identifies the witnesses and provides an overview of their evidence-in-chief and some responses in cross-examination. Witnesses at the trial gave their evidence on affidavit subject to cross-examination. The Lilly witnesses were: 1.Robert Gristwood – Research and Development Director of Arachnova Limited, a British pharmaceutical company. 2.Denis Cherry – Medical Director of the Perth Human Sexuality Centre.3.John Pryor – a medical specialist in the field of uroandrology (relating to the male genital tract).4.William Charman – Professor of Pharmaceutics at the Victorian College of Pharmacy, Monash University.5.Christopher McMahon – a Genito-Urinary Sexual Health Physician at the Australian Centre for Sexual Health, St Leonards, Sydney.6.Lawrence Kruse – a medicinal chemist, consultant to the pharmaceutical and biotechnology industry and former Senior Vice President of Sterling Winthrop.7.Philip Iversen – Principal Research Scientist with Eli Lilly and Company.8.Lothar Uher – a Technical Scientist at ICOS Corporation in the United States.

Decision

Reasons for decision

Having regard to this evidence, it cannot be said that his Honour went beyond what it stated in his reliance upon it. In any event the Patent at claim 8 specified the monocitrate salt and that was disclosed as at the date of grant, complying with the best method disclosure requirement. As at the date of grant, the specification did not contain a false suggestion. Even absent claim 8, we are not persuaded that the reference to the freebase compound rather than the salt has been shown by Lilly to have materially contributed to the grant of the Patent. Lilly’s contention on false suggestion fails. Conclusion As appears from the preceding reasons, Pfizer succeeded in demonstrating error on the part of the learned trial judge in his finding as to lack of inventive step. On the other hand it has not succeeded in its challenge to his Honour’s finding that claim 10 was not fairly based on the specification. None of the Lilly contentions is made out. In the result, however, because of a lack of fair basis, claim 10 is invalid and the orders made by his Honour should stand. The appeal must be dismissed. Having regard to the distribution of success and failure and the ultimate outcome of the appeal, the appropriate order is that each party should bear its own costs of the appeal. I have had the advantage of reading the judgment of French and Lindgren JJ in draft and agree with their Honours’ summary of the facts and the history of these proceedings. I agree also with their account of the arguments as presented by the parties to this appeal. I agree with their reasoning in respect of the issues of infringement and construction and agree also with their conclusion that the importation into or sale in Australia of Cialis would infringe claim 10 of the Patent if that claim is found to be valid. I also agree with French and Lindgren JJ that the primary judge erred in finding that claim 10 of the Patent was invalid because it was obvious or disclosed no inventive step. Further, I agree with their findings in relation to the notional addressee of the Patent, and with their Honours’ assessment of the weight of the evidence concerning obviousness and a lack of inventive step by Pfizer in developing the invention disclosed in the Patent. I also agree with their conclusions in respect of the issues of sufficiency, best method and false suggestion, and their conclusion that none of Lilly’s contentions in the notice of contention is made out.Fair basis While I agree with French and Lindgren JJs’ description of Pfizer’s submissions on the issue of fair basis set out in their draft judgment, I respectfully do not agree with the conclusions they have reached on that issue. Claim 10 is fairly based on the matters disclosed in the body of the specification of the Patent. I have reached this conclusion following an assessment of how the specification of the Patent is to be construed in the light of the common general knowledge and the art as at the priority date. A specification is not to be construed in the abstract. In performing such an analysis, it is well established that the Court is to place itself in the position of some person acquainted with the surrounding circumstances as to the state of the art and manufacture at the time: Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274 at 302 [72]; Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd & Ors (2001) CLR 1 at [24]; see also the judgments of Lockhart and Sheppard JJ in Décor Corporation Pty Ltd v Dart Industries Inc (1998) 13 IPR 385, respectively at 391 and 400.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.